Patent Prosecution
Overview
Technology and the laws meant to protect it—especially the patent laws—are always changing. But the law is not always in sync with technological developments. Companies seeking protection for their state-of-the-art innovations need counsel who not only know what the law is, but where it is likely headed. Crowell & Moring’s team of experienced patent professionals have the experience, knowledge, and judgment to provide such guidance to our clients.
Contacts
Insights
Client Alert | 3 min read | 05.18.26
“To IPR or Not to IPR?” — Director Squires Offers Clarity, With Data and History
For 15 years, the question “Should we file an IPR?” was easy. The answer — almost invariably — was “yes.” High institution rates, a famously skeptical U.S. Patent Trial and Appeal Board (PTAB), and minimal downside made inter partes review (IPR) a nearly reflexive tool in the litigator’s arsenal. U.S. Patent and Trademark Office (USPTO) Director Squires’ precedential decision issued May 14, 2026, in Magnolia Medical Technologies, Inc. v. Kurin, Inc. (IPR2026-00097) provides clarity to that calculus.
Client Alert | 4 min read | 05.12.26
Client Alert | 4 min read | 05.05.26
Insights
EV charging stations & connectors: the importance of design patents
|11.15.24
EV Design & Manufacturing
Professionals
Insights
Client Alert | 3 min read | 05.18.26
“To IPR or Not to IPR?” — Director Squires Offers Clarity, With Data and History
For 15 years, the question “Should we file an IPR?” was easy. The answer — almost invariably — was “yes.” High institution rates, a famously skeptical U.S. Patent Trial and Appeal Board (PTAB), and minimal downside made inter partes review (IPR) a nearly reflexive tool in the litigator’s arsenal. U.S. Patent and Trademark Office (USPTO) Director Squires’ precedential decision issued May 14, 2026, in Magnolia Medical Technologies, Inc. v. Kurin, Inc. (IPR2026-00097) provides clarity to that calculus.
Client Alert | 4 min read | 05.12.26
Client Alert | 4 min read | 05.05.26
Contacts
Insights
Client Alert | 3 min read | 05.18.26
“To IPR or Not to IPR?” — Director Squires Offers Clarity, With Data and History
For 15 years, the question “Should we file an IPR?” was easy. The answer — almost invariably — was “yes.” High institution rates, a famously skeptical U.S. Patent Trial and Appeal Board (PTAB), and minimal downside made inter partes review (IPR) a nearly reflexive tool in the litigator’s arsenal. U.S. Patent and Trademark Office (USPTO) Director Squires’ precedential decision issued May 14, 2026, in Magnolia Medical Technologies, Inc. v. Kurin, Inc. (IPR2026-00097) provides clarity to that calculus.
Client Alert | 4 min read | 05.12.26
Client Alert | 4 min read | 05.05.26














